Read it again.
It says funded to late CY2025 subject to the SP remaining strong (so that options continue to be converted early).
========================
As at 30 June, there was $9m cash. Plus R&D rebate due of about $7m. Total $16m
The AD trial is more expensive than the MDD trial. Spending on the AD trial plus staff costs will be about $4m per quarter.
The SP hasn't remained strong. If it doesn't recover to over 3.75c, nobody will be exercising options at all, let alone doing it early.
Without any revenue from options exercise, ACW is funded to about June 2025.
Read it again.It says funded to late CY2025 subject to the SP...
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
-0.001(4.00%) |
Mkt cap ! $70.68M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.4¢ | $133.5K | 5.461M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 4693575 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 8756804 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| ACW (ASX) Chart |